Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). T...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

HD17 for Intermediate Stage Hodgkin Lymphoma This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) The purpose of this study is to determine the Maximum Tolerated Dose, Dose Limiting Toxicities and optimal dosing schedule of 4SC-202 investigating its safety, tolerability and pharmacokin...

• Pays Germany
• Organes Aucun
• Spécialités Aucune

A Study to Assess AFM13 in Patients With Hodgkin Lymphoma The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin ly...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

EMMA-1 (Erbitux for Multiple Myeloma) EMMA-1 is an open-label, non-randomized, two-stage phase II study. Patients with refractory multiple myeloma stage II or III or relapsed disease after at least one line of treatment will r...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

HD16 for Early Stage Hodgkin Lymphoma This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma The study is designed - to demonstrate efficacy of AFM13 with an optimized treatment schedule - to decide whether AFM13 warrants further investigation in a phase III clinical trial

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) The purpose of this trial is to determine 1. Disease stabilization/response rate after six 21-day cycles of ibrutinib 2. Remission status after six, twelve and 20 21-day cycles of ib...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune